Anaptysbio (ANAB) Revenue (2016 - 2026)
Anaptysbio posted quarterly Revenue of $25.6 million for Q1 2026, down 7.98% year-on-year from $27.8 million in Q1 2025, and down 65.93% on a QoQ basis from $75.0 million in Q4 2025.
Anaptysbio (ANAB) has 11 years of Revenue data on file, last reported at $25.6 million in Q1 2026.
- For the quarter ending Q1 2026, Revenue fell 7.98% year-over-year to $25.6 million; the trailing twelve-month figure through Mar 2026 stood at $172.8 million (up 119.47% YoY), and the FY2025 full-year result was $234.6 million, up 157.01% from the prior year.
- Revenue for Q1 2026 stood at $25.6 million, down from $75.0 million in the prior quarter.
- Across five years, Revenue topped out at $75.0 million in Q4 2025 and bottomed at $970000.0 in Q1 2022.
- The 5-year median for Revenue is $9.0 million (2023), against an average of $16.7 million.
- The widest annual swing landed in 2022, when Revenue tumbled 93.92%; it then surged 422.49% in 2024.
- A 5-year view of Revenue shows it stood at $5.0 million in 2022, then jumped by 80.1% to $9.0 million in 2023, then surged by 177.62% to $25.0 million in 2024, then soared by 200.0% to $75.0 million in 2025, then plunged by 65.93% to $25.6 million in 2026.
- The last three Revenue figures came in at $25.6 million (Q1 2026), $75.0 million (Q4 2025), and $50.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - | 25.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.56 Mn |
| Dec 31, 2025 | 75.00 Mn |
| Sep 30, 2025 | 50.00 Mn |
| Jun 30, 2025 | 22.26 Mn |
| Mar 31, 2025 | 27.77 Mn |
| Dec 31, 2024 | 25.00 Mn |
| Sep 30, 2024 | 15.00 Mn |
| Jun 30, 2024 | 10.97 Mn |
| Mar 31, 2024 | 7.18 Mn |
| Dec 31, 2023 | 9.01 Mn |
| Sep 30, 2023 | 3.32 Mn |
| Jun 30, 2023 | 3.46 Mn |
| Mar 31, 2023 | 1.37 Mn |
| Dec 31, 2022 | 5.00 Mn |
| Sep 30, 2022 | 1.29 Mn |
| Jun 30, 2022 | 1.22 Mn |
| Mar 31, 2022 | 970,000.00 |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 20.00 Mn |
| Jun 30, 2021 | 20.00 Mn |
| Mar 31, 2021 | 10.00 Mn |
| Dec 31, 2020 | 60.00 Mn |
| Mar 31, 2020 | 10.00 Mn |
| Dec 31, 2019 | 3.00 Mn |
| Jun 30, 2019 | 5.00 Mn |
| Sep 30, 2018 | 5.00 Mn |
| Dec 31, 2017 | 3.00 Mn |
| Jun 30, 2017 | 3.00 Mn |
| Dec 31, 2016 | 1.00 Mn |
| Sep 30, 2016 | 1.00 Mn |
| Jun 30, 2016 | 4.00 Mn |
| Mar 31, 2016 | 4.00 Mn |